Hu, S., Liang, S., Guo, H., Zhang, D., Li, H., Wang, X., Yang, W., Qian, W., Hou, S., Wang, H., Guo, Y. and Lou, Z. (2013) Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View. Journal of Biological Chemistry, 288, 27059-27067.
http://dx.doi.org/10.1074/jbc.M113.491530

has been cited by the following article:

• TITLE: Eruptive Lentigines after Adalimumab Therapy

  AUTHORS: Efstathia Pasmatzi, Alexandra Monastirli, Sophia Georgiou, Dionysios Tsambaos

  KEYWORDS: Lentigines, Melanocytes, TNF-α, Adalimumab, Psoriasis

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.5 No.4, April 21, 2016

  ABSTRACT: Adalimumab, a TNF-alpha antagonist, is the first fully humanized recombinant immunoglobulin G1 (IgG1) monoclonal antibody. It is presently widely used in the systemic treatment of rheumatoid arthritis, inflammatory bowel disease, moderate and severe psoriasis and hidradenitis suppurativa. However, its administration is associated with a two-fold risk of severe and possibly fatal infections and in some rare cases with congestive heart failure, lymphoma, lupus-like syndrome, cytopenias, hepatotoxicity and development of demyelinating neurological disorders. Furthermore, the occurrence of various types of melanocytic skin lesions has been reported during treatment with adalimumab. In the present paper we report the case of a female psoriatic patient who developed eruptive lentigines following treatment with this compound.